HDACs dual inhibitors for cancer treatment. Eur J Med Chem 140:392–402. https://doi.org/
10.1016/j.ejmech.2017.09.038
141. Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kürner A, Haas J, Greve G, Haydn T,
Fulda S, Lübbert M, Lüdeke S, Berg T, Sippl W, Schüle R, Jung M (2018) Structure-activity
studies on N-substituted tranylcypromine derivatives lead to selective inhibitors of lysine
specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Eur J
Med Chem 144:52–67. https://doi.org/10.1016/j.ejmech.2017.12.001
142. Mould DP, Alli C, Bremberg U, Cartic S, Jordan AM, Geitmann M, Maiques-Diaz A,
McGonagle AE, Somervaille TCP, Spencer GJ, Turlais F, Ogilvie D (2017) Development of
(4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1.
J Med Chem 60(19):7984–7999. https://doi.org/10.1021/acs.jmedchem.7b00462
143. Li Z-H, Liu X-Q, Geng P-F, Suo F-Z, Ma J-L, Yu B, Zhao T-Q, Zhou Z-Q, Huang C-X,
Zheng Y-C, Liu H-M (2017) Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as
novel LSD1 inhibitors. ACS Med Chem Lett 8(4):384–389. https://doi.org/10.1021/
acsmedchemlett.6b00423
144. Mould DP, Bremberg U, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Small
HF, Somervaille TCP, Ogilvie D (2017) Development of 5-hydroxypyrazole derivatives as
reversible inhibitors of lysine specific demethylase 1. Bioorg Med Chem Lett 27
(14):3190–3195. https://doi.org/10.1016/j.bmcl.2017.05.018
145. Ding L, Wang Z-Z, Sun X-D, Yang J, Ma C-Y, Li W, Liu H-M (2017) 3D-QSAR (CoMFA,
CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyanopyrimidine derivatives to explore the structure requirements of LSD1 inhibitors. Bioorg Med
Chem Lett 27(15):3521–3528. https://doi.org/10.1016/j.bmcl.2017.05.065
146. Sartori L, Mercurio C, Amigoni F, Cappa A, Fagá G, Fattori R, Legnaghi E, Ciossani G,
Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P,
Villa M, Vultaggio S, Botrugno OA, Dessanti P, Minucci S, Zagarrí E, Carettoni D,
Iuzzolino L, Varasi M, Vianello P (2017) Thieno[3,2-b]pyrrole-5-carboxamides as new
reversible inhibitors of histone lysine demethylase KDM1A/LSD1. Part 1: high-throughput
screening and preliminary exploration. J Med Chem 60(5):1673–1692. https://doi.org/10.
1021/acs.jmedchem.6b01018
147. Vianello P, Sartori L, Amigoni F, Cappa A, Fagá G, Fattori R, Legnaghi E, Ciossani G,
Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P,
Villa M, Botrugno OA, Dessanti P, Minucci S, Vultaggio S, Zagarrí E, Varasi M, Mercurio C
(2017) Thieno[3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine
demethylase KDM1A/LSD1. Part 2: structure-based drug design and structure–activity relationship. J Med Chem 60(5):1693–1715. https://doi.org/10.1021/acs.jmedchem.6b01019
148. Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L, Song Y (2016) 3-(Piperidin-4-ylmethoxy)
pyridine containing compounds are potent inhibitors of lysine specific demethylase 1. J Med
Chem 59(1):253–263. https://doi.org/10.1021/acs.jmedchem.5b01361
149. Clissold PM, Ponting CP (2001) JmjC: cupin metalloenzyme-like domains in jumonji, hairless
and phospholipase A2beta. Trends Biochem Sci 26(1):7–9
150. Aik WS, Chowdhury R, Clifton IJ, Hopkinson RJ, Leissing T, McDonough MA, Nowak R,
Schofield CJ, Walport LJ (2015) Chapter 2 introduction to structural studies on
2-oxoglutarate-dependent oxygenases and related enzymes. 2-Oxoglutarate-dependent
oxygenases. The Royal Society of Chemistry, Cambridge, pp 59–94. https://doi.org/10.
1039/9781782621959-00059
151. Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M (2012) The role
of histone demethylases in cancer therapy. Mol Oncol 6(6):683–703. https://doi.org/10.1016/j.
molonc.2012.07.004
152. Hou H, Yu H (2010) Structural insights into histone lysine demethylation. Curr Opin Struct
Biol 20(6):739–748. https://doi.org/10.1016/j.sbi.2010.09.006
Structure-Based Design of Epigenetic Inhibitors
485
10.1016/j.ejmech.2017.09.038
141. Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kürner A, Haas J, Greve G, Haydn T,
Fulda S, Lübbert M, Lüdeke S, Berg T, Sippl W, Schüle R, Jung M (2018) Structure-activity
studies on N-substituted tranylcypromine derivatives lead to selective inhibitors of lysine
specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Eur J
Med Chem 144:52–67. https://doi.org/10.1016/j.ejmech.2017.12.001
142. Mould DP, Alli C, Bremberg U, Cartic S, Jordan AM, Geitmann M, Maiques-Diaz A,
McGonagle AE, Somervaille TCP, Spencer GJ, Turlais F, Ogilvie D (2017) Development of
(4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1.
J Med Chem 60(19):7984–7999. https://doi.org/10.1021/acs.jmedchem.7b00462
143. Li Z-H, Liu X-Q, Geng P-F, Suo F-Z, Ma J-L, Yu B, Zhao T-Q, Zhou Z-Q, Huang C-X,
Zheng Y-C, Liu H-M (2017) Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as
novel LSD1 inhibitors. ACS Med Chem Lett 8(4):384–389. https://doi.org/10.1021/
acsmedchemlett.6b00423
144. Mould DP, Bremberg U, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Small
HF, Somervaille TCP, Ogilvie D (2017) Development of 5-hydroxypyrazole derivatives as
reversible inhibitors of lysine specific demethylase 1. Bioorg Med Chem Lett 27
(14):3190–3195. https://doi.org/10.1016/j.bmcl.2017.05.018
145. Ding L, Wang Z-Z, Sun X-D, Yang J, Ma C-Y, Li W, Liu H-M (2017) 3D-QSAR (CoMFA,
CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyanopyrimidine derivatives to explore the structure requirements of LSD1 inhibitors. Bioorg Med
Chem Lett 27(15):3521–3528. https://doi.org/10.1016/j.bmcl.2017.05.065
146. Sartori L, Mercurio C, Amigoni F, Cappa A, Fagá G, Fattori R, Legnaghi E, Ciossani G,
Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P,
Villa M, Vultaggio S, Botrugno OA, Dessanti P, Minucci S, Zagarrí E, Carettoni D,
Iuzzolino L, Varasi M, Vianello P (2017) Thieno[3,2-b]pyrrole-5-carboxamides as new
reversible inhibitors of histone lysine demethylase KDM1A/LSD1. Part 1: high-throughput
screening and preliminary exploration. J Med Chem 60(5):1673–1692. https://doi.org/10.
1021/acs.jmedchem.6b01018
147. Vianello P, Sartori L, Amigoni F, Cappa A, Fagá G, Fattori R, Legnaghi E, Ciossani G,
Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P,
Villa M, Botrugno OA, Dessanti P, Minucci S, Vultaggio S, Zagarrí E, Varasi M, Mercurio C
(2017) Thieno[3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine
demethylase KDM1A/LSD1. Part 2: structure-based drug design and structure–activity relationship. J Med Chem 60(5):1693–1715. https://doi.org/10.1021/acs.jmedchem.6b01019
148. Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L, Song Y (2016) 3-(Piperidin-4-ylmethoxy)
pyridine containing compounds are potent inhibitors of lysine specific demethylase 1. J Med
Chem 59(1):253–263. https://doi.org/10.1021/acs.jmedchem.5b01361
149. Clissold PM, Ponting CP (2001) JmjC: cupin metalloenzyme-like domains in jumonji, hairless
and phospholipase A2beta. Trends Biochem Sci 26(1):7–9
150. Aik WS, Chowdhury R, Clifton IJ, Hopkinson RJ, Leissing T, McDonough MA, Nowak R,
Schofield CJ, Walport LJ (2015) Chapter 2 introduction to structural studies on
2-oxoglutarate-dependent oxygenases and related enzymes. 2-Oxoglutarate-dependent
oxygenases. The Royal Society of Chemistry, Cambridge, pp 59–94. https://doi.org/10.
1039/9781782621959-00059
151. Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M (2012) The role
of histone demethylases in cancer therapy. Mol Oncol 6(6):683–703. https://doi.org/10.1016/j.
molonc.2012.07.004
152. Hou H, Yu H (2010) Structural insights into histone lysine demethylation. Curr Opin Struct
Biol 20(6):739–748. https://doi.org/10.1016/j.sbi.2010.09.006
Structure-Based Design of Epigenetic Inhibitors
485